Latest Health News

Flagship Investments Limited has reported steady financial health in its latest quarterly filing, confirming a stable loan-to-value ratio and full compliance with convertible note obligations for Q2 2025.

Streamplay Studio Limited has posted a positive operating cash flow for the first time since its acquisition-led growth strategy began, buoyed by strong game launches and a new multi-year licensing agreement with Amazon.

BTC Health has secured a $0.5 million order for its life-saving ECMO equipment from the Women's and Children's Hospital in Adelaide, marking a significant expansion of its specialised medical device network alongside Melbourne's Royal Children's Hospital.

Microba Life Sciences reports strong Q4 FY25 growth driven by record microbiome test sales and clinician adoption in Australia and the UK, while advancing its therapeutics pipeline and targeting regional break-even in FY26.

Microba Life Sciences reports record Q4 FY25 microbiome test sales in Australia and the UK, underpinned by landmark clinical studies and a $14.5 million capital raise. The company is transitioning away from legacy products to focus on high-value diagnostics, positioning for sustained growth in FY26.

dorsaVi reports transformative performance improvements from integrating RRAM technology into its biomedical sensor platforms, promising faster, more durable, and energy-efficient wearable devices.

Papyrus Australia has fully impaired its investments in its Egyptian joint ventures PPYEg and EBFC, citing lack of returns and governance issues ahead of its 2025 audited results.

Bio-Gene Technology Limited has completed the second tranche of its share placement, securing approximately A$2.46 million and issuing unlisted options to investors and its lead manager.

InteliCare Holdings announces CEO Daniel Pilbrow’s resignation effective October 2025, with Non-Executive Director Tim Chapman stepping in as interim executive director during the leadership transition.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

Beacon Minerals has announced a $12 million on-market share buy-back program aiming to enhance shareholder value and capital efficiency, with purchases starting August 1, 2025.

Norwood Systems delivered its strongest quarter yet with record cash inflows, significant debt reduction, and expanding global partnerships, setting a robust foundation for FY2026.